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A c c e p t e d M a n u s c r i p t 3 Currently, there are no effective licensed vaccines or drugs available for the treatment of Zika virus infections and financial support for their development is running short. We suggest that sofosbuvir be considered for Zika infection. Sofosbuvir is used with other drugs for the treatment of hepatitis C virus (HCV) genotypes 1-6 infections. Zika is a member of the flaviviridae family of viruses, which includes yellow fever virus, West Nile virus, dengue virus, St. Louis encephalitis virus and HCV. 1 The most common manifestations include macular or papular rash, fever, arthralgia, retro-orbital pain, conjunctivitis, myalgia and headache and these resolve within two weeks. 2 Zika virus, as with other flaviruses, is an enveloped, single-stranded positive-sensed RNA virus. 4 It has been hypothesized that Zika virus uses the enzyme RNA-dependent RNA polymerase (RdRp or the nonstructural protein, NS5), along with cofactors, to replicate, maintain and express its RNA genome. 4 The three dimensional structure of flavivirus
RdRp resembles that of a cupped right hand and contains a finger, thumb and palm domain and is conserved.
A c c e p t e d M a n u s c r i p t 4 elucidated. However, the predicted three dimensional structure and amino acids for Zika virus RdRp indicates that hepatitis C virus (HCV) RdRp (NS5B protein), particularly at the active site, shares many residues in common with Zika RdRp. 4 Furthermore, the pharmacologically active metabolite of sofosbuvir, 2'-fluoro-2-C-methyl-UTP, which inhibits HCV RdRp, docks into the active site of NS5. 4 Thus, it is possible that certain nucleoside and nucleotide compounds that inhibit HCV RdRp may have inhibitory potency against Zika virus. Zika virus RdRp is an excellent pharmacological target as 1) its inhibition will prevent RNA synthesis and decrease viral replication; 2) there is no similar protein target in human cells.
Sofosbuvir is a uridine nucleotide analog that is biotransformed in hepatocytes to a triphosphate metabolite that inhibits HCV RdRp-catalyzed RNA synthesis, thereby inhibiting viral replication and transcription. 5 Interestingly, the triphosphate metabolite of the nucleoside analog 7-deaza-2'-C-methyladenosine, which inhibits HCV RdRp in vitro, has been shown to: 1) inhibit the in vitro replication of Zika virus, as well as other flaviviruses; 2) significantly decrease Zika viremia and delay morbidity and mortality in Zika-infected mice. 6 Congruent with the above findings, certain 2'-C-methylated nucleosides have been shown to inhibit Zika virus replication in cell cultures. 7 Two recent studies indicate that sofosbuvir significantly fits or docks into the Zika virus RdRp. 8, 9 Furthermore, there is an 80% overlap in amino acid sequence for the Zika and HCV RdRp's that bind sofosbuvir. 9 In vitro data indicate that sofosbuvir inhibits 1)
Brazilian Zika virus RdRp in a concentration-dependent manner; 2) Brazilian Zika viral A c c e p t e d M a n u s c r i p t 5 replication in BHK-21 (baby hamster kidney) and SH-Sy5y (human neuroblastoma) cells. 9 Finally, a recent study has shown that BCX4430, an adenosine nucleoside analog, significantly 1) reduces the cytopathic effect of three different Zika strains in vitro; 2) decreases mortality in AG129 mice (which lack Type I and Type II interferon receptors, 300 mg/kg/day); 3) protects AG129 mice from mortality when given one day after Zika virus challenge. Sofosbuvir has a pharmacokinetic profile that would be suitable for treating the potential variety of patients with Zika virus. For example, at least 80% of a dose of sofosbuvir is absorbed systemically and can be given without regard to food. 11 The primary metabolite of sofosbuvir, GS-331007, is pharmacologically inactive, non-toxic and primarily excreted unchanged into the urine. 11 The kinetics of sofosbuvir are not significantly altered by age (19 to 75 years of age), ethnicity, gender, body mass index or cirrhosis.
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In addition, sofosbuvir and GS-331007 have linear pharmacokinetics with minimal accumulation after multiple dosing. 11 Sofosbuvir has a large volume of distribution (127 liters), thereby increasing the likelihood that sufficient concentrations will be present in potential reservoir areas. Sofosbuvir can be used in patients with severe liver impairment and mild-moderate impairment of renal function.
Safety would not appear to be of major concern as the majority of adverse effects reported for 400 mg of sofosbuvir were of grade 1 severity in HCV patients and only 1% of patients discontinued treatment. 12 Nonetheless, if sofosbuvir produced intolerable or severe adverse effects or increased mortality, then treatment would be promptly discontinued. Patients should be screened for HCV as using sofosbuvir alone for the treatment of HCV would not be considered optimal therapy. Currently, no well 13 In summary, we propose that sofosbuvir is a safe pharmacotherapeutic approach for a Funding: None M a n u s c r i p t
